Cellosaurus LS411N (CVCL_1385)

Cell line name LS411N
Synonyms LS-411N; LS-411; LS411
Accession CVCL_1385
Resource Identification Initiative To cite this cell line use: LS411N (RRID:CVCL_1385)
Comments Part of: AstraZeneca Colorectal cell line (AZCL) panel.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
Doubling time: 23 hours (PubMed=25984343).
Microsatellite instability: Instable (MSI-high) (PubMed=25926053; Sanger).
Sequence variation: APC p.Gln789Ter and p.Thr1556fs*3 (not confirmed by Sanger sequecing) (PubMed=24755471).
Sequence variation: Homozygous for BRAF p.Val600Glu (ATCC; PubMed=12068308; PubMed=24755471).
Sequence variation: PTEN p.Cys105fs*8 and p.Lys164fs*3 (not confirmed by Sanger sequencing) (PubMed=24755471).
Sequence variation: TP53 p.Tyr126Ter (PubMed=16418264; PubMed=24755471).
Omics: Deep exome analysis.
Omics: Deep quantitative phosphoproteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: miRNA expression profiling.
Omics: N-glycan profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Cecum adenocarcinoma (NCIt: C5543)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP

Markers:
AmelogeninX
CSF1PO10,11
D13S31712,13,14,16 (ATCC)
12,13,14 (Cosmic-CLP)
D16S53911,12
D5S8189,15,16,17 (ATCC)
9,15 (Cosmic-CLP)
D7S8207.3,9.3 (ATCC)
8,10 (Cosmic-CLP)
TH016
TPOX8,9
vWA15,16,17 (ATCC)
15,16 (Cosmic-CLP)
Web pages http://www.pawefish.path.cam.ac.uk/ColonCellLineDescriptions/LS411.html
http://tcpaportal.org/mclp/
Publications

PubMed=1389533; DOI=10.1016/0959-8049(92)90031-V
Lahm H., Petral-Malec D., Yilmaz-Ceyhan A., Fischer J.R., Lorenzoni M., Givel J.-C., Odartchenko N.
Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and -6 and antagonistic effects of transforming growth factor beta 1.
Eur. J. Cancer 28:1894-1899(1992)

PubMed=1617643
Suardet L., Gaide A.-C., Calmes J.-M., Sordat B., Givel J.-C., Eliason J.F., Odartchenko N.
Responsiveness of three newly established human colorectal cancer cell lines to transforming growth factors beta 1 and beta 2.
Cancer Res. 52:3705-3712(1992)

PubMed=8895552; DOI=10.1002/(SICI)1097-0215(19960927)68:1<126::AID-IJC22>3.0.CO;2-8
Suardet L., Li C., Little J.B.
Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line.
Int. J. Cancer 68:126-131(1996)

PubMed=10737795; DOI=10.1073/pnas.97.7.3352
Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J., Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.
APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.
Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000)

PubMed=11226274; DOI=10.1073/pnas.041603298
Abdel-Rahman W.M., Katsura K., Rens W., Gorman P.A., Sheer D., Bicknell D.C., Bodmer W.F., Arends M.J., Wyllie A.H., Edwards P.A.W.
Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement.
Proc. Natl. Acad. Sci. U.S.A. 98:2538-2543(2001)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=16418264; DOI=10.1073/pnas.0510146103
Liu Y., Bodmer W.F.
Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006)

PubMed=16854228; DOI=10.1186/1476-4598-5-29
Bandres E., Cubedo E., Agirre X., Malumbres R., Zarate R., Ramirez N., Abajo A., Navarro A., Moreno I., Monzo M., Garcia-Foncillas J.
Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues.
Mol. Cancer 5:29-29(2006)

PubMed=19927377; DOI=10.1002/gcc.20730
Knutsen T., Padilla-Nash H.M., Wangsa D., Barenboim-Stapleton L., Camps J., McNeil N., Difilippantonio M.J., Ried T.
Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines.
Genes Chromosomes Cancer 49:204-223(2010)

PubMed=20606684; DOI=10.1038/sj.bjc.6605780
Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.
5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.
Br. J. Cancer 103:340-346(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23272949; DOI=10.1186/1755-8794-5-66
Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A., Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A., Orphanides G., French T., Wessels L.F.A.
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.
BMC Med. Genomics 5:66-66(2012)

PubMed=23932154; DOI=10.1016/j.radonc.2013.06.032
Salendo J., Spitzner M., Kramer F., Zhang X., Jo P., Wolff H.A., Kitz J., Kaulfuss S., Beissbarth T., Dobbelstein M., Ghadimi M., Grade M., Gaedcke J.
Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g.
Radiother. Oncol. 108:451-457(2013)

PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013
Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.
Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.
Cancer Res. 74:3238-3247(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25926053; DOI=10.1038/ncomms8002
Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.
Nat. Commun. 6:7002-7002(2015)

DOI=10.1101/092767
Roumeliotis T.I., Williams S.P., Goncalves E., Zamanzad G.F., Aben N., Michaut M., Schubert M., Wright J.C., Yang M., Alsinet C., Dienstmann R., Guinney J., Beltrao P., Brazma A., Stegle O., Adams D.J., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.
Genomic determinants of protein abundance variation in colorectal cancer cells.
bioRxiv 2016:092767-092767(2016)

PubMed=26537799; DOI=10.1074/mcp.M115.051235
Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J., Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E., Tollenaar R.A., Rombouts Y., Wuhrer M.
N-glycosylation profiling of colorectal cancer cell lines reveals association of fucosylation with differentiation and caudal type homebox 1 (CDX1)/villin mRNA expression.
Mol. Cell. Proteomics 15:124-140(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ATCC; CRL-2159
Cell line databases/resources CCLE; LS411N_LARGE_INTESTINE
ColonAtlas; LS411
Cosmic-CLP; 907794
GDSC; 907794
LINCS_LDP; LCL-1337
SKY/M-FISH/CGH; 5011
Ontologies CLO; CLO_0007406
Biological sample resources BioSample; SAMN03472557
Chemistry resources ChEMBL-Cells; CHEMBL3308268
ChEMBL-Targets; CHEMBL2366189
Gene expression databases GEO; GSM513913
GEO; GSM514300
GEO; GSM741269
GEO; GSM887280
GEO; GSM888355
GEO; GSM1006219
GEO; GSM1006220
GEO; GSM1006221
GEO; GSM1346848
GEO; GSM1374637
GEO; GSM1448140
GEO; GSM1670061
Metabolomic databases MetaboLights; MTBLS227
Polymorphism and mutation databases Cosmic; 685868
Cosmic; 887215
Cosmic; 907794
Cosmic; 948862
Cosmic; 985999
Cosmic; 995401
Cosmic; 1043821
Cosmic; 1310951
Cosmic; 1312306
Cosmic; 1479613
Cosmic; 1995491
Cosmic; 2301999